Transarterial Chemoembolization

Global Transarterial Chemoembolization Market to Reach US$21.8 Billion by 2030

The global market for Transarterial Chemoembolization estimated at US$16.8 Billion in the year 2024, is expected to reach US$21.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Chemotherapeutic Agents, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$11.5 Billion by the end of the analysis period. Growth in the Radio Therapeutic Agents segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 8.1% CAGR

The Transarterial Chemoembolization market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global "Transarterial Chemoembolization" Market – Key Trends & Drivers Summarized

Why Is Transarterial Chemoembolization Becoming a Standard for Liver Cancer Treatment Worldwide?
Transarterial chemoembolization (TACE) has emerged as a preferred and increasingly standardized therapy for intermediate-stage hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Unlike systemic chemotherapy, TACE delivers high-dose chemotherapy directly into the hepatic artery feeding the tumor while simultaneously blocking the blood supply, leading to targeted drug exposure and localized tumor necrosis. This dual mechanism has proven particularly effective in patients ineligible for surgical resection or liver transplantation. TACE is also being adopted as a bridging therapy for patients awaiting transplantation, helping to stabilize disease progression. Globally, the incidence of liver cancer is rising due to factors such as chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver damage. These trends have increased demand for locoregional therapies like TACE, which offer improved survival rates and disease control with a lower systemic toxicity profile. Emerging guidelines by international oncology societies are endorsing TACE as a frontline or combination treatment for liver malignancies, thereby reinforcing its central role in therapeutic pathways and boosting adoption among healthcare providers worldwide.

How Are Drug Delivery Innovations and Imaging Technologies Enhancing TACE Outcomes?
The effectiveness of TACE has significantly improved through advancements in embolic materials, catheter technology, and imaging guidance systems. Drug-eluting beads (DEBs), which allow for controlled and sustained release of chemotherapy agents at the tumor site, have largely replaced traditional lipiodol-based formulations in many markets, reducing systemic exposure and improving response rates. Technological enhancements in microcatheters and steerable delivery systems have made it possible to navigate complex vascular anatomies with precision, minimizing damage to healthy liver tissue. At the same time, real-time imaging modalities such as cone-beam CT and 3D angiography have revolutionized intra-procedural visualization, allowing for highly targeted delivery and immediate verification of treatment success. These innovations have also paved the way for personalized treatment plans, where tumor size, location, and vascularity are factored into decisions on embolic type, particle size, and dosing schedules. Additionally, the integration of AI in imaging analytics is beginning to assist interventional radiologists in pre-procedural planning and post-procedural outcome assessments, improving consistency and long-term prognoses. These technology-led improvements are not only boosting clinical outcomes but also expanding the candidate pool for TACE.

Is the Global Healthcare Landscape Ready for the Widespread Adoption of TACE?
The global healthcare ecosystem is increasingly receptive to the widespread adoption of transarterial chemoembolization, supported by expanding interventional radiology infrastructure and a growing base of trained specialists. In high-income countries, the presence of sophisticated imaging suites, multidisciplinary tumor boards, and dedicated oncology pathways has allowed for the seamless integration of TACE into liver cancer care algorithms. Meanwhile, middle-income countries are investing heavily in minimally invasive cancer care, recognizing TACE’s value in resource-constrained settings where access to advanced surgery or systemic therapies is limited. In Asia-Pacific, where liver cancer incidence is particularly high, governments are including TACE in public insurance schemes and national cancer control programs, fueling rapid market expansion. Private sector investments in ambulatory surgical centers and oncology-focused hospitals are also contributing to the increased availability of TACE in urban and peri-urban regions. However, challenges remain in low-income countries due to inadequate imaging capabilities and a shortage of skilled interventional radiologists. Efforts by global health organizations to improve access through mobile IR units, training programs, and public-private partnerships are beginning to address these disparities, gradually democratizing access to this life-extending procedure.

The Growth in the Transarterial Chemoembolization Market Is Driven by Several Factors…
The growth in the transarterial chemoembolization market is driven by several factors rooted in disease prevalence, medical innovation, and healthcare system evolution. A primary driver is the rising global burden of liver cancer, fueled by aging populations, viral hepatitis, alcohol consumption, and metabolic disorders. As patient volumes increase, so does the need for intermediate therapies like TACE that fill the treatment gap between curative and palliative care. From a technological perspective, the development of next-generation embolic agents, improved catheter navigation tools, and AI-powered imaging analytics is enhancing procedural efficacy and safety. Healthcare providers are embracing TACE for its minimally invasive profile, shorter recovery times, and lower complication rates compared to systemic chemotherapy or surgery. Additionally, the growing preference for outpatient interventional oncology treatments is expanding demand for TACE in both hospital and specialty clinic settings. Insurance reimbursements, particularly in developed and rapidly developing economies, are being streamlined to cover TACE as a first-line therapy, increasing patient access. Strategic collaborations between device manufacturers, pharma companies, and interventional radiology networks are also fostering innovation and market penetration. Collectively, these factors are positioning TACE as a vital pillar in the multidisciplinary management of liver cancer worldwide.

SCOPE OF STUDY:

The report analyzes the Transarterial Chemoembolization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Chemotherapeutic Agents, Radio Therapeutic Agents, Drug-Eluting Particles); Indication (Unresectable HCC, Early-Stage HCC); End-Use (Hospitals, Clinics, Cancer Research Centers, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Advaxis Inc.
• Bayer AG
• Bellicum Pharmaceuticals
• Boston Scientific Corporation
• CELGENE Corporation
• Cook Medical
• F. Hoffmann-La Roche Ltd
• Hikma Pharmaceuticals PLC
• Isofol Medical AB
• Kaneka Corporation
• Medtronic plc
• Merck & Co., Inc.
• Merit Medical Systems, Inc.
• Nippon Kayaku Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Siemens Healthineers AG
• Sirtex Medical Limited
• Spectrum Pharmaceuticals, Inc.
• Terumo Corporation

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.